Which hedge funds own XENE? XENON PHARMACEUTICALS INC, Q2 2026 13F holders
Healthcare · Open on the interactive board
10 of the hedge funds tracked by WhaleCreep disclosed a position in XENE (XENON PHARMACEUTICALS INC) in their Q2 2026 13F filings, worth $238.9m in total. The largest holder by portfolio weight is Duquesne Family Office LLC at 0.3% of its book. 2 managers opened a new position this quarter: Marshall Wace, Point72 Asset Management LP. 1 exited: Holocene Advisors.
10tracked managers holding
2opened this quarter
1exited this quarter
Which hedge funds hold XENE? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| Duquesne Family Office LLC | Q2 2026 | 0.3% | $14.4m | 238,600 | 0% | held |
| Tudor Investment | Q2 2026 | 0.1% | $32.9m | 545,387 | 10% | added |
| Citadel Advisors | Q2 2026 | 0.0% | $84.6m | 1,401,242 | -47% | reduced |
| Marshall Wace | Q2 2026 | 0.0% | $41.6m | 689,342 | – | new |
| Woodline Partners | Q2 2026 | 0.0% | $9.4m | 155,302 | 3% | added |
| Renaissance Technologies LLC | Q2 2026 | 0.0% | $11.3m | 187,110 | -38% | reduced |
| Millennium Management | Q2 2026 | 0.0% | $22.7m | 376,777 | 87% | added |
| Point72 Asset Management LP | Q2 2026 | 0.0% | $7.9m | 130,378 | – | new |
| Brevan Howard Capital Management | Q2 2026 | 0.0% | $600.3k | 9,945 | -17% | reduced |
| D. E. Shaw & Co | Q2 2026 | 0.0% | $13.5m | 223,922 | 1082% | added |
Exited since the previous quarter
| Manager | Prior weight | Prior value |
|---|---|---|
| Holocene Advisors | 1.1% | $88.3m |
How has hedge fund ownership of XENE changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 10 | $238.9m |
| Q1 2026 | 9 | $325.0m |
| Q4 2025 | 3 | $75.1m |
| Q3 2025 | 5 | $90.4m |
| Q2 2025 | 5 | $64.5m |
| Q1 2025 | 4 | $21.8m |
| Q4 2024 | 5 | $23.2m |
| Q3 2024 | 5 | $52.6m |
| Q2 2024 | 5 | $54.9m |
| Q1 2024 | 5 | $48.3m |
| Q4 2023 | 6 | $93.4m |
| Q3 2023 | 5 | $61.2m |
| Q2 2023 | 4 | $62.8m |
| Q1 2023 | 5 | $70.7m |
| Q4 2022 | 4 | $110.3m |
| Q3 2022 | 4 | $143.6m |
Counts every tracked manager that disclosed XENE in that quarter's filing, including managers that have since stopped filing.